Comparison of major manufacturers and drug quality of Crizotinib

Crizotinib is one of the first approved targeted drugs for ALK positive non-small cell lung cancer. Its main function is to inhibit ALK, ROS1 and some MET receptors can block tumor signaling pathways and inhibit tumor growth. The international original manufacturer of this drug is Pfizer. Since its launch, its strict production process and complete clinical trial data have established its position in ALK targeted therapy. The original crizotinib produced by Pfizer has reliable guarantees in terms of quality, purity and efficacy consistency, and is a globally recognized standard drug.

In the domestic market, in addition to imported original drugs, there are also some domestically produced generic drugs of crizotinib. Domestic drugs have the same active ingredients as original drugs, but there may be differences in production processes, excipient selection, quality control and clinical data support. Although most generic drugs have been approved by the State Food and Drug Administration for marketing, in actual clinical applications, doctors still tend to make a comprehensive trade-off between original drugs and generic drugs based on patients' economic status, efficacy needs, and accessibility.

In terms of drug quality comparison, Pfizer's original drugs are generally better than most generic drugs in terms of stability, purity and dissolution profile consistency, and clinical efficacy and tolerability data fully support their safety. Some domestic generic drugs have been on the market for a short time and have relatively limited real-world usage data, but they can still meet blood concentration and efficacy requirements in most patients. For severe or drug-resistant patients, especially those who are using ALK targeted drugs for the first time, original drugs are often recommended first to ensure efficacy and continuity of treatment.

Generally speaking, the original drug of crizotinib and the generic drug have the same active ingredients, but there are differences in the production process, clinical data support and drug consistency. When patients choose medications, they should weigh them based on doctor's recommendations, financial conditions and drug availability. Purchasing medicines through formal channels and following prescriptions are the keys to ensuring efficacy and safety. For patients on long-term treatment, continuous monitoring of efficacy and adverse reactions can also help determine whether the drug meets their needs.

Reference materials:https://pubmed.ncbi.nlm.nih.gov/25170012/